Anvisa Clears Datroway for EGFR-Mutated Lung Cancer

Media partner

PHARMA · ONCOLOGY · AUGUST 7, 2026 · LATIN AMERICA

Targeted therapy access in Brazil’s oncology market expanded this week as Anvisa, the country’s national health surveillance agency, approved datopotamab deruxtecan — sold under the brand name Datroway — for adults with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), according to the agency’s official announcement.

The approval adds a new antibody-drug conjugate to the treatment landscape for a mutation-defined lung cancer population. EGFR-mutated NSCLC represents a molecularly distinct subset of lung cancer for which targeted sequencing decisions — which agent, in which line of therapy — carry direct consequences for clinical outcomes and for the cost structures of both private health plans and public oncology programs.

Brazil is the largest pharmaceutical market in Latin America, accounting for 42% of regional sales, according to Grazielle Alves, a senior manager at EY-Parthenon. That scale means an Anvisa clearance carries commercial weight beyond the domestic market, signalling to regional distributors and procurement bodies that the molecule has cleared one of the region’s most rigorous regulatory processes.

The more consequential near-term question for payers and hospital systems is not the approval itself but what follows it. Anvisa registration and reimbursement coverage operate on separate institutional tracks in Brazil. ANS, the country’s private-health regulator, governs mandatory coverage obligations for supplementary health plans, while CONITEC, Brazil’s health-technology assessment body, advises on incorporation into the Sistema Único de Saúde (SUS), the public health system. Neither process is triggered automatically by an Anvisa approval, and neither has a fixed resolution timeline tied to the registration date. The announcement does not specify whether a CONITEC submission or ANS coverage review has been initiated.

For the private hospital and oncology clinic segment, the approval creates an immediate procurement decision point: whether to add Datroway to institutional formularies ahead of any reimbursement determination, absorbing cost risk, or to wait for coverage signals from ANS. That sequencing choice is not academic — oncology drugs approved without mandatory coverage can sit in a regulatory limbo where they are legally available but financially inaccessible to most patients.

The operational implication for manufacturers is that Brazilian market entry for an oncology agent now requires parallel engagement across at least three institutional processes: Anvisa registration (completed), ANS coverage negotiation, and CONITEC health-technology assessment for SUS access. Each has its own evidentiary standards and timeline. Press materials accompanying the approval do not detail which of the latter two processes is currently active or at what stage.

The structural gap between regulatory approval and patient-level access in Brazil’s oncology segment is not unique to this molecule — but it is sharpest for high-cost targeted therapies, where the distance between an Anvisa clearance and a funded prescription can be measured in years rather than months.